AlphAIalphai — Financial news for AI agents
marketscreener.comAUG 311 min read$AXSM

Axsome Therapeutics Starts Phase 3 Trial of AXS-05 for Smoking Cessation

Axsome Therapeutics has initiated a Phase 3 trial for AXS-05, a treatment aimed at smoking cessation. The company's stock is currently trading at $199.02, with a 5-day change of -3.51% and a year-to-date change of -4.21%. UBS recently adjusted its price target to $280 from $259, maintaining a Buy rating.

Original reporting
marketscreener.com
Published Aug 31, 2026, 11:36 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 12:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$AXSM
Neutral
medium confidence
Mentioned
$AXSM
Relevance
7/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$AXSMNeutralLow
01

Why it matters

The trial start reduces binary risk but does not provide immediate earnings or revenue guidance. Market reaction will depend on interim data releases.

02

Market read

Primary biotech news with modest short‑term trading relevance; longer‑term upside tied to trial outcomes.

03

What to watch

Competing nicotine‑cessation products and regulatory timelines could dampen upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Axsome Therapeutics (AXSM) is a clinical‑stage biopharma focused on central nervous system disorders. AXS-05 is its oral NMDA antagonist‑antidepressant candidate now being tested for smoking cessation.

Company-level read

Ticker impact

$AXSMNeutralMedium confidence
Context

Axsome Therapeutics announced the initiation of a Phase 3 trial for its AXS-05 smoking‑cessation program.

Expected impact

Modest upside potential if interim data are positive; limited immediate move.

Evidence & confidence

Trial start is material for a biotech but no data yet; market may price in long‑term upside.

Market effects

Sector

Adds to the pipeline momentum in the smoking‑cessation therapeutic space.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond investors tracking biotech pipelines.

Counterpoint

What could challenge this read

Phase 3 failures are common; investors may wait for data before committing.

Key entities

  • Company
    Axsome Therapeutics

    US‑listed biotech developing AXS‑05.

Read at source← All news

Also covered by

3 outlets

Related articles

AUG 31
$AXSMMedAI 8/10

Axsome doses first patient in phase 3 smoking cessation trial

Axsome Therapeutics (AXSM) dosed the first patient in its Phase 3 SUMMIT trial for AXS-05 as a smoking cessation treatment. The study will assess efficacy and safety over 12 weeks. AXS-05 is approved for other uses but not yet for smoking cessation. The company holds patents for the drug until at least 2043. Smoking affects 34 million adults in the U.S., costing over $300 billion annually.

investing.com2 min
AUG 11
$AXSMMed

Axsome Therapeutics Q2 Earnings Call Highlights

Axsome Therapeutics (AXSM) reported Q2 updates on AUVELITY, SYMBRAVO, and SUNOSI, including gross-to-net discounts and prescription growth. AUVELITY was launched for Alzheimer’s agitation, with total prescriptions about 266,000. SYMBRAVO prescriptions rose to about 23,500. FDA accepted AXS-12 NDA with a May 1, 2027 target date. Costs and expenses were also detailed.

yahoo.com6 min
AUG 11
$ABXMed

Barrick Profit Soars, Nvidia Eyes $500B AI Push, M&A Accelerates

The article reports multiple US corporate updates. Barrick Mining said Q2 profit rose 50% to $1.22B, with revenue up 44% to $5.29B, and agreed with Newmont on a $1.95B cash top-up to expand Nevada Gold Mines. Nvidia is working on a $500B AI financing venture; Intel announced a $15B stock offering. It also covers results for Axsome (revenue +46%), Monday.com, RadNet, NESR, and Camtek.

hdfcsky.com7 min